To assess the safety and efficacy of Hizentra™, a 20% human IgG for subcutaneous administration, in a cohort of patients with primary immunodeficiency disorders (PID) after a dose equivalent switch from their previous treatment.
|Home | About | Journals | Submit | Contact Us | Français|
Allergy Asthma Clin Immunol. 2012; 8(Suppl 1): A19.
Published online Nov 2, 2012. doi: 10.1186/1710-1492-8-S1-A19